Related Experiment Video
Updated: May 11, 2025
07:35
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
11.4K
Phenylketonuria as an Adherence Disease.
1Health Education and Promotion Laboratory, Sorbonne Paris Nord University, Bobigny, France.
Patient Preference and Adherence
|April 18, 2025
Summary
Phenylketonuria (PKU) may be an "adherence disease," where high phenylalanine levels impair cognitive function, creating a cycle of nonadherence. This suggests PKU itself hinders dietary compliance, impacting neurocognition.
Area of Science:
- Metabolic Disorders
- Neuroscience
- Patient Adherence Research
Background:
- Phenylketonuria (PKU) is a genetic disorder requiring strict dietary management.
- Traditional adherence barriers include palatability, cost, access, time, and social factors.
- A novel hypothesis suggests PKU's pathophysiology creates a cycle worsening adherence.
Purpose of the Study:
- To explore the novel concept of PKU as an
Main Methods:
- Narrative review of existing literature on PKU pathophysiology and adherence.
- Hypothesizing a feedback loop between phenylalanine levels and executive function.
- Analyzing the implications of PKU impacting adherence capabilities.
Main Results:
- Elevated phenylalanine levels in nonadherent patients may impair cognitive and executive functions.
- This impairment can reduce the ability to adhere to the necessary low-phenylalanine diet.
- PKU's pathophysiology may create a vicious cycle exacerbating adherence challenges.
Conclusions:
- PKU might be considered an "adherence disease" due to its self-exacerbating nature.
- Long-term dietary nonadherence is likely common in PKU.
- Restoring phenylalanine hydroxylase activity is key to mitigating PKU's neurocognitive and psychosocial impacts.
More Related Videos
Related Concept Videos
01:20Inborn Errors of Metabolism
109
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
109
01:21Overview of Protein Metabolism
529
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
529
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
31
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
31
01:16Protein-Drug Binding: Mechanism and Kinetics
144
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
144
01:29Drug Distribution: Plasma Protein Binding
4.4K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
4.4K
01:19Allosteric Proteins-ATCase
5.6K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.6K